March 2015 – WHO published the updated working paper on Sofosbuvir as key medicine for Hep C treatment and describes the relevant patents for Sofosbuvir and providing data where these patents have been filed or granted…read more
Regional advocacy platform for access to Hep C treatment in Asia Pacific wrote to The Secretary of the 20th Expert Committee on the Selection and Use of Essential Medicines supporting MSF’s application to include Daclatasvir in the Model List of Essential Medicines of the World Health Organisation (WHO)...read full letter
